Cell therapy for peripheral artery disease
NG Frangogiannis - Current opinion in pharmacology, 2018 - Elsevier
Patients with severe peripheral artery disease (PAD) who are not candidates for
revascularization have poor prognosis. Cell therapy using peripheral blood-derived or bone …
revascularization have poor prognosis. Cell therapy using peripheral blood-derived or bone …
ALDH1A3 Is the Key Isoform That Contributes to Aldehyde Dehydrogenase Activity and Affects in Vitro Proliferation in Cardiac Atrial Appendage Progenitor Cells
S Puttini, I Plaisance, L Barile, E Cervio… - Frontiers in …, 2018 - frontiersin.org
High aldehyde dehydrogenase (ALDHhi) activity has been reported in normal and cancer
stem cells. We and others have shown previously that human ALDHhi cardiac atrial …
stem cells. We and others have shown previously that human ALDHhi cardiac atrial …
Every PACE counts: learning about blood cells and blood flow in peripheral artery disease
R Bretón-Romero, NM Hamburg - Circulation, 2017 - Am Heart Assoc
Every PACE Counts | Circulation Science Volunteer Warning signs SearchSearch
Advanced Search Donate Circulation logo Hello Guest! MY ALERTS SIGN IN JOIN …
Advanced Search Donate Circulation logo Hello Guest! MY ALERTS SIGN IN JOIN …
[PDF][PDF] Vinnytsya National Medical University na MI Pirogov Department of endoscopic and cardiovascular surgery
DI Grebeniuk - endocvs.vn.ua
Lower extremity peripheral artery disease (PAD) is a major health burden, representing the
third-leading cause of cardiovascular morbidity related to atherosclerotic disease after …
third-leading cause of cardiovascular morbidity related to atherosclerotic disease after …
Alan Hirsch, MD: 1954–2017
WR Hiatt - 2017 - Am Heart Assoc
I have been a close friend and professional colleague of Alan for the past 25 years, primarily
regarding his work in vascular medicine but extending to our personal lives as we journeyed …
regarding his work in vascular medicine but extending to our personal lives as we journeyed …